Comparison of Relative Cerebral Blood Volume and Proton Spectroscopy in Patients with Treated Gliomas

References

1. ↵
   Aronen HJ, Cohen MS, Belliveau JW, Fordham JA, Rosen BR. Ultrafast imaging of brain tumors. Top Magn Reson Imaging 1993;5:14-24

   PubMed
2. Rosen BR, Belliveau JW, Chien D. Perfusion imaging by nuclear magnetic resonance. Magn Reson Q 1989;5:263-281

   PubMed
3. Maeda M, Itoh S, Kimura H, et al. Tumor vascularity in the brain: evaluation with dynamic susceptibility-contrast MR imaging. Radiology 1993;189:233-238

   CrossRefPubMedWeb of Science
4. ↵
   Guckel F, Brix G, Rempp K, Deimling M, Rother J, Georgi M. Assessment of cerebral blood volume with dynamic susceptibility contrast enhanced gradient-echo imaging. J Comput Assist Tomogr 1994;18:344-351

   CrossRefPubMedWeb of Science
5. ↵
   Aronen HJ, Gazit IE, Louis DN, et al. Cerebral blood volume maps of gliomas: comparison with tumor grade and histologic findings. Radiology 1994;191:41-51

   CrossRefPubMedWeb of Science
6. ↵
   Wenz F, Rempp K, Hess T, et al. Effect of radiation on blood volume in low-grade astrocytomas and normal brain tissue: quantification with dynamic susceptibility contrast MR imaging. AJR Am J Roentgenol 1996;166:187-193

   CrossRefPubMed
7. Pardo FS, Aronen HJ, Kennedy D, et al. Functional cerebral imaging in the evaluation and radiotherapeutic treatment planning of patients with malignant glioma. Int J Radiat Oncol Biol Phys 1994;30:663-669

   CrossRefPubMed
8. ↵
   Chang L, McBride D, Miller BL, et al. Localized in vivo 1H magnetic resonance spectroscopy and in vitro analyses of heterogeneous brain tumors. J Neuroimaging 1995;5:157-163

   PubMed
9. McBride DQ, Miller BL, Nikas DL, et al. Analysis of brain tumors using 1H magnetic resonance spectroscopy. Surg Neurol 1995;44:137-144

   CrossRefPubMedWeb of Science
10. Shimizu H, Kumabe T, Tominaga T, et al. Non-invasive evaluation of malignancy of brain tumors with proton MR spectroscopy. AJNR Am J Neuroradiol 1996;17:737-747

    Abstract
11. Go KG, Keuter EJW, Kamman RL, et al. Contribution of magnetic resonance spectroscopic imaging and L-[1–11C]tyrosine positron emission tomography to localization of cerebral gliomas for biopsy. Neurosurgery 1994;34:994-1002

    CrossRefPubMedWeb of Science
12. Heesters MAAM, Kamman RL, Mooyaart EL, Go KG. Localized proton spectroscopy of inoperable brain tumors: response to radiation therapy. J Neurooncol 1993;17:27-35

    CrossRefPubMed
13. Fulham MJ, Bizzi A, Dietz MJ, et al. Mapping of brain tumor metabolites with proton MR spectroscopic imaging: clinical relevance. Radiology 1992;185:675-686

    CrossRefPubMed
14. ↵
    Nelson SJ, Nalbandian AB, Proctor E, et al. Registration of images form sequential MR studies of the brain. J Magn Reson Imaging 1994;4:877-883

    PubMedWeb of Science
15. ↵
    Wald LL, Nelson SJ, Day MR, et al. Serial proton magnetic resonance spectroscopy imaging of glioblastoma multiforme after brachytherapy. J Neurosurg 1997;87:525-534

    CrossRefPubMedWeb of Science
16. Gill SS, Thomas DGT, Van Bruggen N, et al. Proton MR spectroscopy of intracranial tumors: in vivo and in vitro studies. J Comput Assist Tomogr 1990;14:497-504

    CrossRefPubMedWeb of Science
17. ↵
    Villringer A, Rosen BR, Belliveau JW, et al. Dynamic imaging with lanthanide chelates in normal brain: contrast due to magnetic susceptibility effects. Magn Reson Med 1988;6:164

    CrossRefPubMedWeb of Science
18. ↵
    Fisel CR, Ackerman JL, Buxton RB, et al. MR contrast due to microscopically heterogeneous magnetic susceptibility: numerical simulations and applications to cerebral physiology. Magn Reson Med 1991;17:336-347

    CrossRefPubMedWeb of Science
19. Edelman RR, Mattle HP, Atkinson DJ, et al. Cerebral blood flow: assessment with dynamic contrast-enhanced T2*-weighted MR imaging at 1.5 T. Radiology 1990;176:211-220

    CrossRefPubMed
20. Belliveau JW, Rosen BR, Kantor HL, et al. Functional cerebral imaging by susceptibility-contrast NMR. Magn Reson Med 1990;14:538-546

    CrossRefPubMedWeb of Science
21. Rempp KA, Brix G, Wenz F, Becker C, Guckel F, Lorenz W. Quantification of regional cerebral blood flow and volume with dynamic susceptibility contrast-enhanced MR imaging. Radiology 1994;193:637-641

    CrossRefPubMedWeb of Science
22. Boxerman JL, Hamberg LM, Rosen BR, Weisskoff RM. MR contrast due to intravascular magnetic susceptibility perturbations. Magn Reson Med 1995;34:555-566

    CrossRefPubMedWeb of Science
23. Kennan RP, Zhong J, Gore JC. Intravascular susceptibility contrast mechanisms in tissues. Magn Reson Med 1994;31:9-21

    CrossRefPubMedWeb of Science
24. Larson KB, Perman WH, Perlmutter JS, Gado MH, Ollinger JM, Zierler K. Tracer-kinetic analysis for measuring regional cerebral blood flow by dynamic nuclear magnetic resonance imaging. J Theor Biol 1994;170:1-14

    CrossRefPubMed
25. Perman WH, Mokhtar HG, Larson KB, Perlmutter JS. Simultaneous MR acquisition of arterial and brain signal-time curves. Magn Reson Med 1992;28:74-83

    CrossRefPubMedWeb of Science
26. Donahue KM, Weisskoff RM, Chesler DA, et al. Improving MR quantification of regional blood volume with intravascular T1 contrast agents: accuracy, precision, and water exchange. Magn Reson Med 1996;36:858-867

    CrossRefPubMed
27. Press WH, Flannery BP, Teukolsky SA, Vetterling WT. Numerical Recipes in C. Cambridge: Cambridge University Press; 1988
28. ↵
    Janus TJ, Kim EE, Tilbury R, Bruner JM, Yung WKA. Use of [18F]fluorodeoxyglucose positron emission tomography in patients with primary malignant brain tumors. Ann Neurol 1993;33:540-548

    CrossRefPubMedWeb of Science
29. Di Chiro G, DeLaPlaz RL, Brooks RA, et al. Glucose utilization of cerebral gliomas measured by F-18-fluorodeoxyglucose and positron emission tomography. Neurology 1982;32:1323-1329

    Abstract/FREE Full Text
30. DeLaPlaz RL, Patronas NJ, Brooks RA, et al. Positron emission tomography study of gray-matter glucose utilization by brain tumors. AJNR Am J Neuroradiol 1983;4:826-829

    Abstract/FREE Full Text
31. Di Chiro G. Positron emission tomography using F-18-fluorodeoxyglucose in brain tumors: a powerful diagnostic and prognostic tool. Invest Radiol 1983;22:360-371